ESMO 2025: Prostate cancer highlights
Episode 6. Alicia Morgans and Karim Fizazi review pivotal ESMO Congress 2025 data from trials such as MAGNITUDE, CAPTURE, CAPItello-280, and PSMAddition, which are reshaping HRR mutation testing and clinical management in metastatic prostate cancer. Fizazi emphasizes the importance of assay concordance and cautions against over-reliance on single blood-based tests, especially in younger patients with strong family histories. They examine the prognostic weight of HRR mutations, underscoring the need for vigilant follow-up and closer monitoring. Fizazi shares a nuanced perspective on radioligand therapy, noting the modest benefit of the treatment being assessed in PSMAddition and calling for further data before shifting clinical practice. Their discussion challenges current practice and highlights what clinicians need to watch for next. View transcript.
Chapters
00:28 Key findings from ESMO 2025
03:47 Interpreting results from MAGNITUDE
08:46 Key insights from CAPTURE and more
11:00 ESMO 2025: What’s next in HRR testing?
15:26 PSMAddition: Radioligand tx in mHSPC
19:22 ESMO 2025: Practice-changing data
Meet the guest speaker
Karim Fizazi, MD, PhD
Karim Fizazi is a medical oncologist at Institut Gustave Roussy and full professor in oncology at the University of Paris Saclay in Villejuif, France. Fizazi is the president of the French Groupe d’Etude des Tumeurs Genito-Urinaires (GETUG) and head of the GU oncology group at Gustave Roussy.
Disclosures: Amgen, Arvinas, Astellas, AstraZeneca, Bayer, Clovis, CureVac, Daiichi Sankyo, Janssen, MacroGenics, MSD, Novartis (Advanced Accelerator Applications), Orion, Pfizer, and Sanofi.
of interest
are looking at
saved
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.